Anti-Müllerian hormone in premenopausal women following treatment of uterine cervical cancer.
Acta Obstet Gynecol Scand
; 93(9): 949-53, 2014 Sep.
Article
en En
| MEDLINE
| ID: mdl-24985038
ABSTRACT
In this longitudinal study we prospectively enrolled 32 premenopausal women (ages 23-44 years) with stage I-III uterine cervical cancer undergoing surgery and/or chemoradiation. Serum levels of anti-Müllerian hormone, follicle-stimulating hormone and estradiol were examined at baseline and 1 year after treatment. As expected, serum anti-Müllerian hormone was undetectable after salpingo-oophorectomy or chemoradiation. After radical hysterectomy and pelvic lymphadenectomy with ovarian preservation serum anti-Müllerian hormone declined from a mean value of 2.0 ± 1.4 µg/L to 1.1 ± 0.8 µg/L (p = 0.01), representing a 45% reduction, whereas there was no significant change in serum levels of follicle-stimulating hormone and estradiol. This implies that ovarian function may be affected not only by castrating treatment but also by radical hysterectomy with ovarian preservation. The risk of premature menopause and the potential need of hormone replacement therapy among these women may be overlooked since they no longer menstruate.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Cuello Uterino
/
Hormona Antimülleriana
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2014
Tipo del documento:
Article